New inhaled combo aims to fight stubborn lung infections in cystic fibrosis
Disease control
Completed
This study tested an inhaled drug called RSP-1502, which combines the antibiotic tobramycin with a substance called CaEDTA, in 71 people with cystic fibrosis who have chronic Pseudomonas lung infections. The goal was to check safety and find the right dose. Participants received …
Phase: PHASE1, PHASE2 • Sponsor: Respirion Pharmaceuticals Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC